Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.

@article{Signore2009CombinedRA,
  title={Combined riluzole and sodium phenylbutyrate therapy in transgenic amyotrophic lateral sclerosis mice.},
  author={Steven J Del Signore and Daniel J Amante and Jinho Jay Kim and Edward C. Stack and Sarah Kay Goodrich and Kerry A. Cormier and Karen M. Smith and Merit Ester Cudkowicz and Robert Ferrante},
  journal={Amyotrophic lateral sclerosis : official publication of the World Federation of Neurology Research Group on Motor Neuron Diseases},
  year={2009},
  volume={10 2},
  pages={85-94}
}
Recent evidence suggests that transcriptional dysregulation may play a role in the pathogenesis of amyotrophic lateral sclerosis (ALS). The histone deacetylase inhibitor, sodium phenylbutyrate (NaPB), is neuroprotective and corrects aberrant gene transcription in ALS mice and has recently been shown to be safe and tolerable in ALS patients while improving hypoacetylation. Since many patients are already on riluzole, it is important to ensure that any proposed therapy does not result in negative… CONTINUE READING